A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503772-24-00

Acronym

VT-001-0050

Enrollment

216

Registered

2023-04-28

Start date

2021-09-15

Completion date

Unknown

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA Nephropathy

Brief summary

Phase 2b_01. Urine protein to creatinine ratio (UPCR) week 24. Phase 3_01. Urine protein to creatinine ratio (UPCR) week 36, Phase 3_01. Urine protein to creatinine ratio (UPCR) week 36

Detailed description

Phase 2b_01. Urine protein to creatinine ratio (UPCR) week 36. Phase 3_01. Annualized Rate of change in eGFR (ie., annualized eGFR total slope) week 104, Phase 3_01. Annualized Rate of change in eGFR (ie., annualized eGFR total slope) week 104

Interventions

DRUGPlacebo of Atacicept

DRUGAtacicept

DRUGENALAPRIL

DRUGLOSARTAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Phase 2b_01. Urine protein to creatinine ratio (UPCR) week 24. Phase 3_01. Urine protein to creatinine ratio (UPCR) week 36, Phase 3_01. Urine protein to creatinine ratio (UPCR) week 36	—

Secondary

Measure	Time frame
Phase 2b_01. Urine protein to creatinine ratio (UPCR) week 36. Phase 3_01. Annualized Rate of change in eGFR (ie., annualized eGFR total slope) week 104, Phase 3_01. Annualized Rate of change in eGFR (ie., annualized eGFR total slope) week 104	—

Countries

Belgium, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026